newsfilter
← Latest News
GlobeNewswire·

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpointsBitopertin NDA resubmission planned by end of 2026, with an FDA decision for